SI3442578T1 - Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka - Google Patents

Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka

Info

Publication number
SI3442578T1
SI3442578T1 SI201731120T SI201731120T SI3442578T1 SI 3442578 T1 SI3442578 T1 SI 3442578T1 SI 201731120 T SI201731120 T SI 201731120T SI 201731120 T SI201731120 T SI 201731120T SI 3442578 T1 SI3442578 T1 SI 3442578T1
Authority
SI
Slovenia
Prior art keywords
cancer
agents
determining
treatment
methods
Prior art date
Application number
SI201731120T
Other languages
English (en)
Inventor
Irving L. Weissman
Mark P. Chao
Ravindra Majeti
Jie Liu
Jens-Peter Volkmer
Original Assignee
The Board Of Trustees Of The Leland Standford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Standford Junior University filed Critical The Board Of Trustees Of The Leland Standford Junior University
Publication of SI3442578T1 publication Critical patent/SI3442578T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201731120T 2016-04-15 2017-04-14 Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka SI3442578T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US201662427679P 2016-11-29 2016-11-29
EP17783254.0A EP3442578B1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer

Publications (1)

Publication Number Publication Date
SI3442578T1 true SI3442578T1 (sl) 2022-05-31

Family

ID=60042716

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731120T SI3442578T1 (sl) 2016-04-15 2017-04-14 Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka

Country Status (12)

Country Link
US (3) US11472878B2 (sl)
EP (2) EP4074339A1 (sl)
JP (3) JP2019515899A (sl)
KR (3) KR20230035435A (sl)
CN (3) CN115350276A (sl)
AU (1) AU2017250809B2 (sl)
CA (1) CA3019676A1 (sl)
ES (1) ES2909835T3 (sl)
PL (1) PL3442578T3 (sl)
PT (1) PT3442578T (sl)
SI (1) SI3442578T1 (sl)
WO (1) WO2017181033A1 (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11779631B2 (en) 2016-11-03 2023-10-10 Pfizer Inc. CD47 blockade therapy by HDAC inhibitors
JP7308191B2 (ja) 2017-10-18 2023-07-13 フォーティ セブン, インコーポレイテッド 抗cd47剤ベースの卵巣癌療法
CN111699005A (zh) 2018-02-12 2020-09-22 四十七公司 使用抗cd47抗体和抗cd20抗体的抗癌方案
WO2020009725A1 (en) * 2018-07-05 2020-01-09 Trican Biotechnology Co., Ltd Human anti-cd47 antibodies and uses thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
KR20210094610A (ko) 2018-11-26 2021-07-29 포티 세븐, 인코포레이티드 c-Kit에 대한 인간화 항체
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
KR20220113353A (ko) 2019-09-18 2022-08-12 람캅 바이오 알파 에이지 Ceacam5 및 cd3에 대한 이중특이적 항체
MX2022006578A (es) 2019-12-17 2022-07-04 Pfizer Anticuerpos especificos para cd47, pd-l1 y sus usos.
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2740823T3 (es) 2008-01-15 2020-02-06 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
EP4349868A2 (en) 2010-05-14 2024-04-10 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
WO2013109752A1 (en) 2012-01-17 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University High affinity sirp-alpha reagents
PL2812443T3 (pl) 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
ES2944477T3 (es) 2013-02-06 2023-06-21 Inhibrx Inc Anticuerpos CD47 no reductores de plaquetas y no reductores de glóbulos rojos y métodos de uso de los mismos
WO2014149477A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
CN105143876B (zh) 2013-03-27 2018-04-20 豪夫迈·罗氏有限公司 生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
EP2992089B1 (en) 2013-04-29 2021-09-08 The Board of Trustees of the Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
EP3052119B1 (en) 2013-10-01 2018-08-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2017181033A1 (en) 2017-10-19
US20230406923A1 (en) 2023-12-21
EP3442578B1 (en) 2022-02-09
ES2909835T3 (es) 2022-05-10
US11718670B2 (en) 2023-08-08
JP2024059764A (ja) 2024-05-01
PL3442578T3 (pl) 2022-06-20
JP2022172278A (ja) 2022-11-15
CA3019676A1 (en) 2017-10-19
AU2017250809B2 (en) 2024-02-29
CN115350276A (zh) 2022-11-18
US20190106491A1 (en) 2019-04-11
JP2019515899A (ja) 2019-06-13
PT3442578T (pt) 2022-05-19
KR20180134367A (ko) 2018-12-18
CN117695387A (zh) 2024-03-15
EP4349412A2 (en) 2024-04-10
KR20240016445A (ko) 2024-02-06
US20230068235A1 (en) 2023-03-02
EP3442578A1 (en) 2019-02-20
US11472878B2 (en) 2022-10-18
EP3442578A4 (en) 2019-04-10
JP7442591B2 (ja) 2024-03-04
KR20230035435A (ko) 2023-03-13
KR102505253B1 (ko) 2023-03-02
AU2017250809A1 (en) 2018-10-25
CN109152837A (zh) 2019-01-04
EP4074339A1 (en) 2022-10-19

Similar Documents

Publication Publication Date Title
PT3442578T (pt) Métodos para determinar e alcançar doses terapêuticas eficazes de agentes anti-cd47 no tratamento do cancro
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
HK1257249A1 (zh) 使用脂質體伊立替康和parp抑制劑用於癌症治療的組合療法
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
IL266198A (en) Liposomal formulation for use in cancer treatment
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
IL266182A (en) Farensyltransferase inhibitors for use in cancer treatment methods
HK1245096A1 (zh) 用於癌症治療的細胞治療劑以及使用該細胞治療劑的聯合治療
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
HUE045185T2 (hu) Új terápiás vegyület és terápiában történõ alkalmazása
GB201600637D0 (en) Therapeutic treatment methods and apparatus for use therein
GB201612793D0 (en) Therapeutic use of quesnoin in colorectal cancer treatment
GB201612794D0 (en) Therapeutic use of diethanololeamide in prostate cancer treatment
AU2016905362A0 (en) Compounds and use thereof in methods of treatment
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201418640D0 (en) Agents and methods for treatment of cancer